ScreenerHero

KPRX Kiora Pharmaceuticals, Inc.

NAS · US · Healthcare · Biotechnology · kiorapharma.com
2.530USD+1.20%Mkt Cap: 11.19M $P/E: —

Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, engages in the development and commercialization of therapies for the treatment of ophthalmic diseases. Its lead product is KIO-301, a poten…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap11.19M USD
Enterprise Value-597.48K USD
Revenue (TTM)—
Gross Profit-3.88M USD
Net Income (TTM)-10.84M USD
Revenue/Share—
Last Price2.530 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees13
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-1.12
PEG—
EV/EBITDA0.06
EV/Revenue—
P/S—
P/B0.66
EPS (TTM)-2.43
EPS (Forward)-2.23
52W Range
1.76565% of range2.950
52W High2.950 USD
52W Low1.765 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-67.19%
ROA-44.67%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-9.96M USD
CapEx (TTM)110.79K USD
FCF Margin—
FCF Yield-56.85%
Net Debt-16.51M USD
Net Debt/EBITDA1.70
Balance Sheet
Debt/Equity0.02
Current Ratio8.97
Quick Ratio8.33
Book Value/Sh3.81 USD
Cash/Share2.65 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay DateAug 30, 2019
Splits
Last Split1:9
Split DateJun 11, 2024
Analyst Consensus
Rating—
Target (Mean)12.00 USD
Upside (mean)+374.3%
Target Range12.00 USD – 12.00 USD
# Analysts1
Ownership
Shares Out.4.42M
Float3.85M
Insiders8.91%
Institutions36.35%
Short Interest
Short Ratio0.3d
Short % Float0.09%
Short % Out.0.09%
Shares Short4.02K
Short (prev mo.)2.94K
Technical
SMA 502.598 (-2.6%)
SMA 2002.390 (+5.9%)
Beta-0.21
S&P 52W Chg16.45%
Avg Vol (30d)13.42K
Avg Vol (10d)8.41K
Technical Indicators
RSI (14)45.0
MACD-0.0161
MACD Signal0.0003
MACD Hist.-0.0163
BB Upper2.752 USD
BB Middle2.604 USD
BB Lower2.456 USD
BB Width11.36%
ATR (14)0.0893 USD
Vol Ratio (20d)1.61x